Resolian, a global bioanalytical and analytical sciences partner supporting drug development and multi-regional clinical trials, has announced leadership changes as the company expands its global footprint and operational capabilities.
 
Rob Stachlewitz will join Resolian as Chief Executive Officer (CEO), while current CEO Pat Bennett will transition into the newly created role of Chief Business Officer and President of Scientific Affairs.

CEO Transition

Incoming CEO Rob Stachlewitz joins Resolian with an impressive track record, having most recently served as Corporate Vice President and General Manager at Charles River, where he oversaw their largest site.
 
Stachlewitz brings 15 years of pharmaceutical R&D experience, having held key roles at Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble. As CEO, Stachlewitz will guide Resolian through its next phase of strategic growth, enhancing its operational capabilities and global presence.
 
Meanwhile, as Chief Business Officer and President of Scientific Affairs, Pat Bennett will focus on growing new service capabilities and enhancing customer relationships, leveraging his 30+ years of experience in bioanalytical sciences and business development. Bennett will also oversee several critical functions to foster client collaboration and synergies across the Resolian team.